Clinical trials
Vasculitis clinical trials
Below are recruiting vasculitis clinical trials, each written for real people, not researchers. We’re tracking 100 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05935709Recruiting
Danish database study for GCA or PMR
This study builds and uses a Danish database for people diagnosed with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR). It may help doctors learn more about these conditions over time and improve care.
AarhusAges 50 years+ - NCT06056921RecruitingPhase 1
CAR T-cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
Taiyuan, ShanxiAges 18 years+ - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT06316076RecruitingPhase 1
CD19 CAR-T cell therapy for autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
ShanghaiAges 18–65 - NCT06335888RecruitingPhase 2
Testing a new imaging agent for large vessel vasculitis
This study tests a special radioactive tracer, 18F-AzaFol, to see if it can help diagnose large vessel vasculitis, a type of inflammation in the arteries. The results will be compared with standard FDG PET/CT scans.
BernAges 50 years+ - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06462768Recruiting
Study of immune cell activity in systemic sclerosis
This study looks at a specific type of immune cell activity (called neutrophil extracellular traps) in the blood of people with systemic sclerosis, other connective tissue diseases, and healthy volunteers. It aims to understand how these cells may be involved in the disease and could lead to better treatments.
ReimsAges 18 years+ - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06593041Recruiting
Platelets in lupus and other autoimmune diseases
This study looks at how platelets (small blood cells that help with clotting) might play a role in autoimmune diseases like lupus. By understanding this, researchers hope to find new ways to treat these conditions.
Strasbourg, FranceAges 18–70 - NCT06599411Recruiting
Skin biomarkers for inflammatory disease treatment
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
ParisAges 18 years+ - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT06676384RecruitingPhase 4
Testing additional drugs for IgA nephropathy in South Asian patients
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Nadiād, GujaratAges 18–65 - NCT06685042RecruitingPhase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Rome, LazioAges 18–65 - NCT06696027Recruiting
Loss of Y chromosome in autoimmune and lung disease
This study looks at how the loss of the Y chromosome in blood cells may be linked to autoimmune and lung diseases in older men. By joining, you help researchers understand this connection better.
Bonn, North Rhine-WestphaliaAges 50 years+ - NCT06698614Recruiting
Magnetic resonance imaging to study kidney disease
This study uses a special MRI scan to look at the kidneys in people with different kinds of kidney disease, including acute kidney injury, chronic kidney disease, vasculitis, and after a kidney transplant. The goal is to better understand these conditions.
EdinburghAges 18 years+ - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT06775912RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Lianyungang, JiangusAges 18–70 - NCT06779799Recruiting
Study of vocal cord lesions in autoimmune disease patients
This study examines vocal cord lesions, like 'bamboo' nodes, that cause voice changes (dysphonia) in people with autoimmune diseases such as lupus or rheumatoid arthritis. It aims to better understand and characterize these lesions to improve diagnosis and treatment.
BrestAges 18 years+ - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06868290RecruitingPhase 2
CAR-T cell therapy for severe GPA or MPA
This trial tests a new CAR-T cell treatment (rapcabtagene autoleucel) for people with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). It aims to see if this therapy can help control the disease by targeting certain immune cells.
Aurora, ColoradoAges 18–75 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+
Hear when a new Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for vasculitis?
- Yes. Clin2 currently lists 100 recruiting vasculitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vasculitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vasculitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.